Open AccessPrognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
Author(s) -
Jennifer Tom,
Min Bao,
Larry Tsai,
Aditi Qamra,
David Summers,
Montserrat CarrascoTriguero,
Jacqueline McBride,
Carrie M. Rosenberger,
Celia J F Lin,
Will Stubbings,
Kevin G. Blyth,
Jordi Carratalà,
Bruno François,
Thomas Benfield,
Derrick S. Haslem,
Paolo Bonfanti,
Cor H. van der Leest,
Nidhi Rohatgi,
Lothar Wiese,
Charles Edouard Luyt,
Farrah Kheradmand,
Iván O. Rosas,
Fang Cai
Publication year - 2021
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000005229
Subject(s) - medicine , tocilizumab , placebo , pneumonia , randomized controlled trial , mechanical ventilation , clinical trial , odds ratio , disease , pathology , alternative medicine
To explore candidate prognostic and predictive biomarkers identified in retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, ferritin, lymphocytes, monocytes, neutrophils, d-dimer, and platelets) in patients with coronavirus disease 2019 pneumonia after treatment with tocilizumab, an anti-interleukin-6 receptor antibody, using data from the COVACTA trial in patients hospitalized with severe coronavirus disease 2019 pneumonia.